Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy, Volume Seven, describes the fundamental aspects of efflux pumps of the ATP-binding cassette superfamily in cancer resistance pathways, along with strategies to target and improve chemotherapy efficacy. Pumps of the ATP-binding cassette superfamily (ABCs) regulate the access of drugs to the intracellular space. In this context, the overexpression of ABCs is a well-known mechanism of multidrug resistance in cancer and is associated with therapeutic failure. Cancer types discussed include breast, endocrine, hematologic, gastrointestinal, musculoskeletal, lung, skin and central nervous system cancers.
The book is a valuable source for researchers and advanced students in cancer, biology, pharmacology, pharmaceutical sciences, biomaterials and medical/clinical sciences that are interested in accessing a comprehensive compendium on efflux pumps in mechanisms of cancer resistance.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
1. Introduction 2. Efflux transporters in cancers resistance: Molecular and functional identification and characterization of P-glycoprotein 3. Efflux transporters in cancers resistance: Molecular and functional identification and characterization of Multidrug Resistance Proteins 4. Efflux transporters in cancers resistance: Molecular and functional identification and characterization of breast cancer resistance protein 5. Molecular imaging of the activity of membrane efflux transporters in cancer 6. Endocrine cancers 7. Hematologic cancers 8. Gastrointestinal cancers 9. Musculoskeletal cancers 10. Lung cancers 11. Skin cancers 12. Cancers of the central nervous system 13. Cancer stem cells 14. Blood-brain barrier and CNS tumors 15. Nanomedicines to overcome efflux transporter-mediated resistance in cancer 16. Pluronic®: The first nanomedicine ABC inhibitor translated into the clinics 17. Cancer therapy with antibody-linked conjugates and MDR expression